ReviewJournal of translational medicine2026
Exercise-modulated IL-6 in cancer cachexia: molecular mechanisms and therapeutic potential.
Review in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Context-dependent regulation of IL-6 in exercise and colorectal cancer cachexia.Frontiers in oncology · 2026Review
- A robust and scalable immunoadsorbent platform based on the high-affinity M03-IgG antibody for targeted IL-6 Removal in cytokine storm.Frontiers in immunology · 2026Article
- Exerkines in diabetic retinopathy: from mechanisms to therapeutic prospects.Frontiers in endocrinology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundCancer cachexia is a multifactorial metabolic syndrome marked by progressive skeletal muscle wasting, systemic inflammation, reduced quality of life, and poor clinical outcomes. Interleukin-6 (IL-6) is a central mediator in cachexia pathophysiology, driving inflammatory signaling, catabolic metabolism, and muscle atrophy. However, IL-6 also rises transiently during exercise, where it exerts beneficial metabolic and anti-inflammatory effects, highlighting the context-dependent nature of IL-6 signaling. MAIN BODY: This review summarizes current knowledge on the regulation and function of IL-6 in cancer cachexia and examines how exercise training modulates IL-6 production and downstream signaling pathways. We focus on the mechanistic differences between chronic, tumor-derived IL-6 and acute, exercise-induced IL-6, particularly their divergent effects on the JAK/STAT3, NF-κB, and AMPK cascades. In addition, we review preclinical and clinical evidence demonstrating that exercise can attenuate cachexia by reprogramming inflammatory responses, preserving skeletal muscle mass, and improving metabolic homeostasis.
conclusionsAccumulating evidence indicates that structured exercise interventions may represent a promising non-pharmacological adjunct to counteract IL-6-driven cancer cachexia and improve patient outcomes. Future research should aim to optimize exercise prescriptions and explore potential synergistic effects between exercise and IL-6-targeted therapies to enhance therapeutic efficacy in cachectic cancer patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.